Arbutus Biopharma Corp. (ABUS) fundamentals score
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. It is currently developing imdusiran (AB-729), its proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 6.9 out of 10, Mixed fundamentals
- Growth: 6.3/10
- Profitability: 7.9/10
- Financial health: 9.1/10
- Earnings quality: 3.2/10
- Valuation: 6.7/10
Scores are calculated from Arbutus Biopharma Corp.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10